Otsuka Australia Pharmaceutical Pty Ltd
Quick facts
Phase 3 pipeline
- Subcutaneous azacitidine · Oncology
Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: